Stocktoria
MASIMO CORP MASI
MASIMO CORP (MASI) earns a Piotroski F-score of 7/9 (strong financial health), with an Altman Z″ in the safe zone. It pays a dividend (safety: no dividend). FY2026 revenue was $1.5B at a -9.9% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -3.64 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 2036 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 7/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.326 |
| Retained earnings / assets | 0.788 |
| EBIT / assets | 0.182 |
| Equity / liabilities | 0.738 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| MASI | MASIMO CORP | 7/9 | 6.71 | — | +9.4% |
| LIVN | LivaNova PLC | 4/9 | 0.72 | — | +10.7% |
| CNMD | CONMED Corp | 5/9 | 2.97 | 23 | +5.2% |
| ITGR | Integer Holdings Corp | 6/9 | 3.52 | 31 | +8% |
| TMDX | TransMedics Group, Inc. | 6/9 | 4.04 | 12.4 | +37.1% |
| AXGN | Axogen, Inc. | 5/9 | -0.43 | — | +20.2% |
| OM | Outset Medical, Inc. | 6/9 | -9.87 | — | +5.1% |
About MASIMO CORP
Masimo Corporation engages in the development, manufacture, and marketing of various patient monitoring technologies, and automation and connectivity solutions worldwide. It offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo Rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of oxygen, carboxyhemoglobin, and methemoglobin. It also provides brain function and hemodynamic monitoring solutions; patient position and activity tracking, and neuromodulation technology solutions; and Masimo Hospital Automation platform, including hospital automation solutions, including Patient SafetyNet, Iris, iSirona, Replica, and UniView; and brain function monitoring, hemodynamic monitoring, regional oximetry, acoustic respiration rate monitoring, capnography and gas monitoring, and telehealth solutions. In addition, the company provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers. Masimo Corporation was incorporated in 1989 and is headquartered in Irvine, California.
FAQ
Is MASI financially healthy?
MASIMO CORP's Piotroski F-score is 7/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does MASI pay a dividend, and is it safe?
Yes. MASIMO CORP pays a dividend with a None payout ratio, rated “no dividend” for safety.
How profitable is MASI?
In FY2026, MASIMO CORP had a net margin of -9.9% and a return on equity of -21.0%.
What is the analyst price target for MASI?
The average Wall-Street price target for MASIMO CORP is $180.00, from 3 analysts (consensus: hold).
Is MASI a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on MASIMO CORP: a Piotroski F-score of 7/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2026-01-03. Facts plus Stocktoria's own computed scores — not investment advice.